(NASDAQ:ATEX), WOODLAND PARK, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) — Anterix (NASDAQ: ATEX), the leading provider of private wireless broadband spectrum for utilities today announced changes in the executive leadership team that further position the company to deliver transformative connectivity solutions to utilities and a growing set of critical infrastructure sectors. Anterix's new senior leaders […]

(NASDAQ:INKT), Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD) Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head

(NASDAQ:CYTK), Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Clinical Research presentations and one poster presentation, at the

(NasdaqGM:LPAA), HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic

(NasdaqGM:LPAA), HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic

(NASDAQ:ZVRA), MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA offers the established efficacy and safety of sodium phenylbutyrate in a novel and convenient formulation for the

(NasdaqGM:NTLA), Completed patient enrollment within nine months with nearly half enrolled from the U.S. Expect to report Phase 3 topline data in the first half of 2026 On track to submit BLA in the second half of 2026 for an anticipated U.S. launch in the first half of 2027 Plan to present additional data from

(NASDAQ:AVAH), ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH) today announced the closing of its refinanced first lien credit facility. The refinanced credit facility provides for the refinancing of the $886.0 million principal balance of existing first lien term loans, the additional borrowing of $439.0 million in incremental first

Austin, TX, USA, Sept. 18, 2025 (GLOBE NEWSWIRE) — Custom Market Insights has published a new research report titled “Beetroot Powder Market Size, Trends and Insights By Product (Conventional, Organic), By Application (Food & Beverage, Nutraceuticals & Dietary Supplements, Cosmetics & Personal Care, Others), By Distribution Channel (Online, Offline), and By Region – Global Industry

(NasdaqGM:BWMN), RESTON, Va., Sept. 18, 2025 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, has been awarded a contract to provide planning and design services relating to the redevelopment of the West End Container Yard at Barbours Cut Terminal in the Port of Houston. The selection